Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety study of cell culture-derived versus egg-derived trivalent influenza vaccine in at-risk children and adolescents
2013-002080-26Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2013
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of cell culture-derived trivalent subunit influenza vaccine and influenza vaccine, inactivated, surface antigen in influenza (2 arms), sponsored by Novartis. Primary endpoints: Solicited adverse events, Unsolicited adverse events and 1 more. Started Jun 2013; status: completed.
02
Drugs
cell culture-derived trivalent subunit influenza vaccineinfluenza vaccine, inactivated, surface antigen
03
Conditions
influenza
Beyond the preview
Go deeper on 2013-002080-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002080-26.